CSS
HEPA

Cubist Systematic Strategies’s Hepion Pharmaceuticals HEPA Stock Holding History

Cubist Systematic Strategies’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-16
Closed -$18K – 3642
2021
Q4 		$18K Buy
+16
New +$21.9K ﹤0.01% 3381

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
ML
McAdam LLC Philadelphia, Pennsylvania $2.59B AUM 21.24% 1-Year Est. Return

Cubist Systematic Strategies's HEPA Position: Q1 2022 in Review

Cubist Systematic Strategies sold out of Hepion Pharmaceuticals (HEPA) in Q1 2022, closing a stake of 16 shares — an estimated $18K sold.

Cubist Systematic Strategies first reported a position in HEPA in Q4 2021 and held it in 1 quarter. The position peaked at $18K in Q4 2021. 31 funds tracked by Wall St. Rank hold HEPA as of Q1 2022.

  • Cubist Systematic Strategies reported no remaining Hepion Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 16 Hepion Pharmaceuticals shares in Q1 2022, an estimated $18K.
  • Cubist Systematic Strategies first reported a position in Hepion Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Cubist Systematic Strategies's Hepion Pharmaceuticals position peaked at $18K in Q4 2021.
  • 31 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2022.

Based on Cubist Systematic Strategies's 13F filing for Q1 2022, filed 16 May 2022.